Politico March 18, 2024
A psychedelic drug selected by artificial intelligence for its promise to precisely target mental illness faces a critical test at the Food and Drug Administration.
The FDA is expected to decide in the next few weeks whether to approve an application by San Francisco-based Mindstate Design Labs for a clinical trial of the psychedelic drug 5-MeO-MiPT.
Why it matters: Approval would mark a win for two hot areas in drug development: psychedelics thought to have promise in treating conditions like depression and post-traumatic stress disorder, and AI, which drugmakers hope will speed products to market.
Mindstate Design Labs picked the drug, also known as moxy, using an AI model it built and trained on more than 70,000 “trip reports” of...
Today's Sponsors
Today's Sponsor